OxySure Systems, Inc. (OXYS) Research Update Released
New York, NY - August 22, 2014 (www.investorideas.com newswire) Taglich Brothers released an updated research report on OxySure Systems, Inc. (OXYS) reiterating a Speculative Buy rating and maintaining a 12-month price target of $2.10. The report noted the following key investment considerations:
- OxySure's oxygen generating technology has lifesaving potential in the treatment of cardiac arrest, acute asthma or pneumonia, severe trauma, smoke inhalation, carbon monoxide poisoning and air embolism.
- OXYS's Model 615, easy to use and quickly brought to bear, is a highly suitable companion for automatic external defibrillators (AEDs). There are an estimated 2.2 million AEDs in service worldwide, roughly 60% of them in the US. OxySure aims to position the Model 615 alongside AEDs in public and private venues.
- European regulatory approval and distribution agreements covering Europe, Asia and South America will support strong revenue gains. The company recently secured the first of two Australian regulatory approvals. As the OxySure Model 615 gains traction, revenue should increase to $18 million by 2017.
- We project narrowing losses as revenue ramps from $1.8 million in 2013 to $4.9 million in 2015. By our estimates OXYS should break even in 2015.
- Equity raised in 2013 has strengthened the company's balance sheet considerably, potentially enabling OXYS to cover cash needs through 2015 without further borrowing.
- In 2Q14 (results released Aug. 14, 2014), OXYS earned revenue of $356,000, up 48%, but incurred a loss of ($0.02) per share. We projected a loss of ($0.01) per share on revenue of $458,000.
- We project continued losses in 2014 but a sharp increase in revenue should enable the company to break even and turn cash flow positive in 2015.
The full report can be viewed at http://www.taglichbrothers.com/equityuniverse/companies/oxysure/oxysure.aspx.
OxySure Systems, Inc. (OXYS: OTCQB), based in Frisco, Texas, manufactures and markets the FDA-approved OxySure Model 615, a low cost, lightweight portable catalytic oxygen generator for medical emergency use. Oxysure's technology offers lifesaving potential in cases of major adverse cardiac events, severe trauma, and respiratory distress.
The company's technology rapidly generates medically pure oxygen by combining two inert powders, obviating the need for storage in compressed tanks or other oxygen generators that pose explosion or fire hazards.
The OxySure Model 615 can be prepositioned in educational institutions, manufacturing facilities, commercial and government office buildings, sports stadia, restaurants, airports, military installations and a wide variety of other public venues for emergency administration of acute oxygen therapy by untrained non-medical persons. Broad emergency application potential prior to arrival of first responders or admission to a medical treatment facility underlies the appeal of the Model 615.
The OxySure 615 is sold through more than 40 independent commission agents in the US and overseas distributors in Australia and New Zealand, the UK, Brazil, South Africa and Turkey.
OXYS also distributes automatic external defibrillators, more than two million of which are in service worldwide for the treatment of cardiac arrest victims before the arrival of first responders. The company's model 615 generator is an ideal companion medical device that can rapidly administer the oxygen needed to resuscitate patients who suffer unexpected major adverse cardiac events.
Taglich Brothers, Inc. is full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
The Taglich Brothers' Equity Research department is dedicated to providing research reports that are informative, insightful and illuminating. Reports are designed to distill volumes of investment information into a concise, straightforward format so that busy professional investors can make informed investment decisions.
The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. In September 2012 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for a minimum of three more months for such services.For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.
This news is published on the Investorideas.com Newswire and its syndicated partner network
Get free news alerts:
Sign up here
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.